Valuation: Atossa Therapeutics, Inc.

Market Cap 25.95M 23.17M 21.4M 19.4M 36.29M 2.46B 36.89M 258M 102M 1.29B 97.37M 95.3M 4.07B P/E 2026 *
-0.69x
P/E 2027 * -0.93x
Enterprise Value 25.95M 23.17M 21.4M 19.4M 36.29M 2.46B 36.89M 258M 102M 1.29B 97.37M 95.3M 4.07B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day-4.41%
1 week-10.65%
Current month+33.33%
1 month+19.27%
3 months+7.88%
6 months-54.62%
Current year-70.62%
1 week 2.38
Extreme 2.38
2.85
1 month 1.82
Extreme 1.82
3.12
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
14.85
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
43.62
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 2009-03-31
Director of Finance/CFO 50 2025-10-13
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Chairman 75 2009-03-31
Director/Board Member 64 2009-03-31
Director/Board Member 79 2011-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
5/12/26
Ensisheim Partners LLC
OtherCompany 0 0% -
5/12/26 Free

Director

10,000 0.1161%
5/12/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
-4.41%-10.65%-81.06%-73.74% 25.95M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.19%+1.11%+36.45%+134.42% 38.31B
Weighted average by Cap. +0.39%+2.73%+47.56%+158.56%

Financials

2026 *2027 *
Net sales - -
Net income -35.3M -31.52M -29.12M -26.39M -49.37M -3.35B -50.18M -350M -139M -1.76B -132M -130M -5.53B -38.03M -33.96M -31.37M -28.43M -53.18M -3.61B -54.06M -377M -149M -1.89B -143M -140M -5.96B
Net Debt - -
Projected Income Statement - Annual - Atossa Therapeutics, Inc.
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
26-10-23 $2.600 -4.41% 77,024
26-10-22 $2.720 +7.51% 90,656
26-10-21 $2.530 -0.39% 189,632
26-10-20 $2.540 -0.78% 36,755
26-10-19 $2.560 -12.03% 80,522
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Atossa Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.600USD
Average target price
19.00USD
Spread / Average Target
+630.77%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Atossa Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. ATOS Stock